BiotechTube

avdoralimab

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

COVID

Conditions

COVID

Trial Timeline

Apr 27, 2020 → Mar 30, 2021

NCT ID
NCT04371367

About avdoralimab

avdoralimab is a phase 2 stage product being developed by Innate Pharma for COVID. The current trial status is completed. This product is registered under clinical trial identifier NCT04371367. Target conditions include COVID.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04371367Phase 2Completed

Competing Products

20 competing products in COVID

See all competitors
ProductCompanyStageHype Score
Favipiravir + NitazoxanideStrides PharmaPhase 2
51
Human COVID-19 immunoglobulin (pH4) for intravenous injection + PlaceboSinopharmPhase 2
51
mavrilimumabKiniksa PharmaceuticalsPhase 2/3
60
Mavrilimumab + PlaceboKiniksa PharmaceuticalsPhase 2
47
Mavrilimumab + PlacebosKiniksa PharmaceuticalsPhase 2
47
Mavrilimumab + PlacebosKiniksa PharmaceuticalsPhase 2
47
Gimsilumab + PlaceboRoivant SciencesPhase 2
49
Icosapent ethylAmarin CorporationApproved
77
Icosapent ethylAmarin CorporationPhase 2
44
Bamlanivimab + Placebo + EtesevimabEli LillyPhase 3
77
GX-03 + Petrolatum ointmentTurn TherapeuticsPhase 2
44
Cytotoxic T LymphocytesTevogen BioPhase 1
25
InfliximabCelltrionPhase 2
52
CT-P63 and CT-P66 / PlaceboCelltrionPhase 3
77
DS-5670a + PlaceboDaiichi SankyoPhase 1/2
41
Enzalutamide PillAstellas PharmaPhase 2
52
S-892216 + PlaceboShionogiPhase 2
52
S-892216 + CarbamazepineShionogiPhase 1
33
EnsitrelvirShionogiPhase 2
52
FOY-305 + PlaceboOno PharmaceuticalPhase 3
77

Other Products from Innate Pharma

IPH2101Phase 2
44
IPH5201 + durvalumab + standard chemotherapyPhase 2
44
IPH4102Phase 2
44
IPH2101Phase 2
44
Lacutamab + Gemcitabine + OxaliplatinePhase 2
44